ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 4L

Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials

Megan E. B. Clowse1, Daniel J Wallace2, Richard Furie3, Michelle Petri4, Marilyn Pike5, Piotr Leszczynski6, C Michael Neuwelt7, Kathryn Hobbs8, Mauro Keiserman9, Liliana Duca10, Kenneth Kalunian11, Sabine Bongardt12, Christian Stach12, Carolyn Beaudot13, Brian Kilgallen13, Catrinel Galateanu14 and Caroline Gordon15,16, 1Rheumatology, Duke University, Durham, NC, 2Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 3North Shore LIJ Health System, Manhasset, NY, 4Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 5Med Pharm Consulting Inc, Cambridge, MA, 6Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, 7Division of Rheumatology, Alameda County Medical Center, Oakland, CA, 8Denver Arthritis Clinic, Denver, CO, 9School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, 10Clinica Neomed, Brasov, Romania, 11UCSD School of Medicine, La Jolla, CA, 12UCB Pharma, Monheim, Germany, 13UCB Pharma, Raleigh, NC, 14UCB Pharma, Brussels, Belgium, 15Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 16NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: October 27, 2015

Keywords: B cells, BILAG, Biologic agents, Biologics and systemic lupus erythematosus (SLE), Late-Breaking 2015

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 10, 2015

Session Title: ACR Late-breaking Abstract Session

Session Type: ACR Late-breaking Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

In phase 2b trials, epratuzumab,
a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion,
significantly improved disease activity in patients (pts) with
moderate-to-severe SLE.1 We report the first data from two phase 3,
randomized, double-blind, placebo (PBO)-controlled, multicenter studies of
epratuzumab in active, moderate-to-severe SLE: EMBODY 1™ (SL0009, NCT01262365)
and EMBODY 2™ (SL0010, NCT01261793).
  Methods:

Pts were ≥18
years of age from North and South America, Europe, Australia, Asia and Africa. Entry
requirements included ANA ≥1:80 and/or anti-dsDNA positivity, ≥4 ACR
revised criteria, SLEDAI-2K score ≥6, BILAG-2004 ≥1 A or ≥2 Bs
in mucocutaneous, musculoskeletal or cardiorespiratory domains and receipt of stable
dose CS (5–60 mg/day prednisone equivalent) for ≥5±1 days prior to baseline
(BL). Temporary CS dose increases ≤25% of BL dose were permitted until
Week (Wk) 8. Pts with BILAG A grade renal or central nervous system domain
scores were excluded.

Pts were randomized
1:1:1 to PBO, IV epratuzumab 600 mg every wk (QW) or 1200 mg every other wk
(QOW) in addition to their standard of care (SOC) therapies, stratified by
region and BL disease severity. Drug or PBO was administered for a 4-wk period
at the beginning of each 12-wk treatment cycle for 4 cycles (48 wks total).

The primary endpoint
was the Wk48 responder rate according to the BILAG-based Combined Lupus
Assessment (BICLA) definition, requiring all of the following: BILAG
improvement and no worsening (all BILAG As at entry improved to B/C/D; all Bs
improved to C/D; no new BILAG As and ≤1 new BILAG B), no worsening in
SLEDAI score, no worsening in physician’s global assessment of disease activity,
no disallowed changes in concomitant medications. Secondary efficacy variables included
BICLA response at Wks 36/24/12. CS use was evaluated.

Efficacy data are
presented for the full analysis set. Missing values were imputed using modified
non-responder imputation with missing data incorporated as the worst possible
outcome. Safety data were comprehensively assessed.

Results:

In EMBODY™ 1, 793 pts
were randomized, 786 (99.1%) received study medication, and 528 (66.6%)
completed the study. In EMBODY™ 2, 791 pts were randomized, 788 (99.6%)
received study medication, and 533 (67.4%) completed the study. BL
characteristics were similar across groups (Table A).

Neither study met the
primary endpoint: Wk48 BICLA response rates in epratuzumab+SOC groups were not
statistically different from PBO+SOC groups (Table B). No significant
differences were seen in other efficacy measures.

No new safety signals
were identified (Table B).

Conclusion:

BICLA response rates
at Wk48 were no different in SLE patients treated with epratuzumab+SOC compared
to PBO+SOC. The safety profile of epratuzumab was similar to previous studies.

1.    Wallace D. Ann Rheum Dis
2014;73:183–90

 


Disclosure: M. E. B. Clowse, UCB Pharma, 5; D. J. Wallace, Bristol-Myers Squibb, Genentech, Biogen IDEC Inc, GlaxoSmithKline, Human Genome Sciences Inc, MedImmune, Novo Nordisk and UCB Pharma, 5; R. Furie, Bristol-Myers Squibb, UCB Pharma, 5; M. Petri, UCB Pharma, 2,GlaxoSmithKline, MedImmune, Merck Serono, Parexel and UCB Pharma, 5; M. Pike, UCB Pharma, 5; P. Leszczynski, None; C. M. Neuwelt, GlaxoSmithKline, Human Genome Sciences, UCB Pharma, 5; K. Hobbs, None; M. Keiserman, None; L. Duca, None; K. Kalunian, Genentech, Biogen IDEC Inc, Cephalon, Cypress, MedImmune, Novo Nordisk, UCB Pharma, 2,Bristol-Myers Squibb, Genentech, Biogen, IDEC Inc, Anthera, MedImmune, Novo Nordisk, Zymogenetics, Serono, UCB Pharma, 5; S. Bongardt, UCB Pharma, 3; C. Stach, UCB Pharma, 3; C. Beaudot, UCB Pharma, 3; B. Kilgallen, UCB Pharma, 3; C. Galateanu, UCB Pharma, 3; C. Gordon, UCB, 2,UCB,, 5,Merck Pharmaceuticals, 5,Paraxel, 5,Eli Lilly and Company, 8.

To cite this abstract in AMA style:

Clowse MEB, Wallace DJ, Furie R, Petri M, Pike M, Leszczynski P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian K, Bongardt S, Stach C, Beaudot C, Kilgallen B, Galateanu C, Gordon C. Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-epratuzumab-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus-results-from-two-phase-3-randomized-placebo-controlled-trials/. Accessed February 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-epratuzumab-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus-results-from-two-phase-3-randomized-placebo-controlled-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.